Phase I Clinical Trial Working for me

Discussion Board Forums Good News / What’s Working Phase I Clinical Trial Working for me

Viewing 14 posts - 1 through 14 (of 14 total)
  • Author
    Posts
  • #58795
    gavin
    Moderator

    Hi Kathy,

    More great news! Great stuff and thanks for sharing it with us all! Love hearing these good news stories and I hope that they continue for you!

    Hugs,

    Gavin

    #58794
    pamela
    Spectator

    Kathy,

    Happy to hear the great news. Keep up the great work.

    Love, -Pam

    #58793
    kathyb
    Member

    Tiffany,

    I got the terrible face “rash”. It actually looked like the worse case of acne a teenage boy could have. My oncologist put me on Minocycline HCL 100 mg caps twice daily. I think it’s an antibiotic, but evidently not a really strong one because it doesn’t work for other infections I might get. This med has worked wonders for me in keeping my face clear and it doesn’t affect my stomach as other antibiotics do.

    Cindy,

    My view is that a clinical trial is a great hope. Right now I would rather be on a clinical trial than standard chemo for cc. Maybe I have to think this way since I’m on a clinical trial :)

    God bless all of you,
    Kathy

    #58792
    candrews
    Spectator

    My Oncologist was hinting on Friday that at some point I might have to be in a clinical trial. He is running out of chemo options to treat me :-(

    Cindy

    #58791
    tiff1496
    Member

    Thanks for the info!!

    Are you having a face rash due to Traceva? I do, and I can’t get it under control!

    #58790
    kathyb
    Member

    Tiffany,

    GDC-0449 is also called vismodegib – brand name: Erivedge. It was just approved for “metastatic or recurrent locally advanced basal cell carcinoma in adults who cannot be treated with surgery or radiation.” That’s not what I have so it is not FDA approved for cc. The National Cancer Institute pays for this drug on my trial.

    http://www.cancer.gov/cancertopics/druginfo/fda-vismodegib

    Kathy

    #58789
    tiff1496
    Member

    Good news!! What is the GDC-0449? I’m already on Erlotinib.

    #58788
    maria
    Spectator

    WOW this is wonderful!! Hope!!!!!

    #58787
    gavin
    Moderator

    Hi Kathy,

    What great news! Thanks so much for sharing and I hope that the good news continues to roll for you! Looking forward to hearing more good news from you!

    Hugs,

    Gavin

    #58786
    marions
    Moderator

    Thanks Kathy, nice to know which control group you are in. I wonder how the other group is fairing? Guess, we will have to wait for the report to come out.
    Hugs,
    Marion

    #58785
    kathyb
    Member

    Marion,

    Yes, I receive Gemcitabine once a week for three weeks in a row. Then a week off. The oral drugs are taken daily.

    Kathy

    #58784
    marions
    Moderator

    Kathy….great, great, news. Are you in the control group receiving Gemcitabine also?

    http://clinicaltrials.gov/ct2/show/NCT00878163

    Hugs,
    Marion

    #58783
    lainy
    Spectator

    Kathy, another MIRACLE HERO! This is such great news! What a way to Spring in to Spring so full of HOPE. Keep up the good work, you are much loved and we are looking for more good news!

    #6496
    kathyb
    Member

    Great MRI report! Original tumor stable. Three new tumors on liver can’t be seen. Spot by stomach shrinking. Enlarged lymph node on spine shrinking. Tumor markers went down 60 some points.

    This is a phase I clinical trial. There have been 55 people nation wide (at all three Mayo sites) on it and they have extended it to 55-65 more people. I have been on this trial longer than anyone (since July 11) and it’s working for me.

    http://clinicaltrials.mayo.edu/clinicaltrialdetails.cfm?trial_id=100871

    Thanks be to God!

    (Original diagnosis July 09 – inoperable Klatskin tumor, cholangiocarcinoma, stage IV, prognosis 3-14 months)

Viewing 14 posts - 1 through 14 (of 14 total)
  • The forum ‘Good News / What’s Working’ is closed to new topics and replies.